Login / Signup

Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.

Vanessa L MerkerHeather L ThompsonPamela L WoltersFrank D BuonoCynthia M HingtgenTena RosserBelinda BartonCarolina BarnettTaylor SmithDiana HaberkampMiranda L McManusAndrea BaldwinIrene P MossClaas RöhlStaci Martin
Published in: Clinical trials (London, England) (2023)
The Response Evaluation in Neurofibromatosis and Schwannomatosis patient-reported outcome working group currently recommends the FACE-Q Craniofacial Module Appearance Distress scale to evaluate patient-reported changes in appearance concerns in clinical trials for neurofibromatosis 1-related plexiform or cutaneous neurofibromas. Additional research is needed to validate this measure in people with neurofibromatosis 1, including older adults and those with tumors in various body locations, and explore the effects of nontumor manifestations on appearance concerns in people with neurofibromatosis 1 and schwannomatosis.
Keyphrases
  • clinical trial
  • patient reported
  • patient reported outcomes
  • physical activity
  • phase ii
  • clinical practice
  • open label
  • study protocol
  • phase iii
  • double blind